Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells

International Journal of Cancer

Volumn 127, Issue 10, 2010, Pages 2300-2312

  Venetz, Daniel ^a   Ponzoni, Maurilio ^b   Schiraldi, Milena ^a   Ferreri, Andrés J M ^b   Bertoni, Francesco ^c   Doglioni, Claudio ^d   Uguccioni, Mariagrazia ^a  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

cell migration; chemokines; DLBCL; PCNSL; perivascular microenvironment

Indexed keywords

CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CORTICOSTEROID; CXCL9 CHEMOKINE; GRANZYME B; STROMAL CELL DERIVED FACTOR 1; CXCL12 PROTEIN, HUMAN; CXCL9 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BRAIN EDEMA; CANCER SIZE; CD8+ T LYMPHOCYTE; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; LEUKOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; NUCLEOTIDE SEQUENCE; PERICYTE; PHENOTYPE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION; B LYMPHOCYTE; BIOSYNTHESIS; BRAIN TUMOR; CELL MOTION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PATHOLOGY; VASCULARIZATION;

ADULT; AGED; B-LYMPHOCYTES; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOKINE CXCL12; CHEMOKINE CXCL9; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RECEPTORS, CXCR3; RECEPTORS, CXCR4;

EID: 78049502210     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25236     Document Type: Article

References (52)

1. Montesinos-Rongen M, Siebert R, Deckert M,. Primary lymphoma of the central nervous system: just DLBCL or not? Blood 2009; 113: 7-10.
2. Hochberg FH, Baehring JM, Hochberg EP,. Primary CNS lymphoma. Nat Clin Pract Neurol 2007; 3: 24-35.
3. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, Park PJ, McKinney M,. Pathway analysis of primary central nervous system lymphoma. Blood 2008; 111: 3200-210.
4. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature 2008; 454: 436-44.
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
6. Zou W,. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
7. Trapani JA, Sutton VR,. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol 2003; 15: 533-43.
8. Gattinoni L, Powell DJ, Jr, Rosenberg SA, Restifo NP,. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-93.
9. Engelhardt B, Ransohoff RM,. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005; 26: 485-95.
10. Ponzoni M, Berger F, Chassagne-Clement C, Tinguely M, Jouvet A, Ferreri AJ, Dell'Oro S, Terreni MR, Doglioni C, Weis J, Cerati M, Milani M, et al. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol 2007; 138: 316-23.
11. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT,. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003; 101: 815-21.
12. Mazzucchelli L, Blaser A, Kappeler A, Scharli P, Laissue JA, Baggiolini M, Uguccioni M,. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest 1999; 104: R49-54.
13. Vermi W, Lonardi S, Bosisio D, Uguccioni M, Danelon G, Pileri S, Fletcher C, Sozzani S, Zorzi F, Arrigoni G, Doglioni C, Ponzoni M, et al. Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol 2008; 216: 356-64.
14. Clark-Lewis I, Vo L, Owen P, Anderson J,. Chemical synthesis, purification, and folding of C-X-C and C-C chemokines. Methods Enzymol 1997; 287: 233-50.
15. Paoletti S, Petkovic V, Sebastiani S, Danelon MG, Uguccioni M, Gerber BO,. A rich chemokine environment strongly enhances leukocyte migration and activities. Blood 2005; 105: 3405-12.
16. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
17. Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, Baggiolini M,. Actions of the chemotactic cytokines MCP-1. MCP-2, MCP-3, RANTES, MIP-1a and. MIP-1b on human monocytes. Eur J Immunol 1995; 25: 64-8.
18. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B,. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000; 192: 1553-62.
19. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, Forster R,. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000; 192: 1545-52.
20. Vinuesa CG, Tangye SG, Moser B, Mackay CR,. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5: 853-65.
21. Montesinos-Rongen M, Brunn A, Bentink S, Basso K, Lim WK, Klapper W, Schaller C, Reifenberger G, Rubenstein J, Wiestler OD, Spang R, la-Favera R, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 2008; 22: 400-5.
22. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A, Wakeham A, Patterson B, Ohashi PS, Mak TW,. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997; 275: 540-3.
23. Brustle A, Heink S, Huber M, Rosenplanter C, Stadelmann C, Yu P, Arpaia E, Mak TW, Kamradt T, Lohoff M,. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007; 8: 958-66.
24. Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, Colombat P, Hoang-Xuan K, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006; 107: 190-6.
25. Lu R,. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol 2008; 29: 487-92.
26. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A,. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
27. Loetscher P, Seitz M, Baggiolini M, Moser B,. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996; 184: 569-77.
28. Hess C, Means TK, Autissier P, Woodberry T, Altfeld M, Addo MM, Frahm N, Brander C, Walker BD, Luster AD,. IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood 2004; 104: 3463-71.
29. Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, Copeland NG, Bazan JF, Moore KW, Schall TJ, Zlotnik A,. Lymphotactin: a cytokine that represents a new class of chemokine. Science 1994; 266: 1395-9.
30. Brunn A, Montesinos-Rongen M, Strack A, Reifenberger G, Mawrin C, Schaller C, Deckert M,. Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol 2007; 114: 271-6.
31. Smith JR, Falkenhagen KM, Coupland SE, Chipps TJ, Rosenbaum JT, Braziel RM,. Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol 2007; 127: 633-41.
32. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA,. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002; 100: 3853-60.
33. Sebastiani S, Danelon G, Gerber B, Uguccioni M,. CCL22-induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first beta-strand of chemokine. Eur J Immunol 2005; 35: 746-56.
34. Weber C, Koenen RR,. Fine-tuning leukocyte responses: towards a chemokine 'interactome'. Trends Immunol 2006; 27: 268-73.
35. Jahnke K, Coupland SE, Na IK, Loddenkemper C, Keilholz U, Korfel A, Stein H, Thiel E, Scheibenbogen C,. Expression of the chemokine receptors CXCR4. CXCR5, and. CCR7 in primary central nervous system lymphoma. Blood 2005; 106: 384-5.
36. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
37. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-69.
38. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006; 107: 2112-22.
39. Prineas JW, Wright RG,. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978; 38: 409-21.
40. Tanaka R, Iwasaki Y, Koprowski H,. Ultrastructural studies of perivascular cuffing cells in multiple sclerosis brain. Am J Pathol 1975; 81: 467-78.
41. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM,. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-15.
42. Campanella GS, Tager AM, El Khoury JK, Thomas SY, Abrazinski TA, Manice LA, Colvin RA, Luster AD,. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc Natl Acad Sci USA 2008; 105: 4814-19.
43. Willimsky G, Czeh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, Stein H, Blankenstein T,. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008; 205: 1687-1700.
44. Huber M, Brustle A, Reinhard K, Guralnik A, Walter G, Mahiny A, von LE, Lohoff M,. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci USA 2008; 105: 20846-51.
45. Zangani MM, Froyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, Thompson KM, Munthe LA, Bogen B,. Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med 2007; 204: 1181-91.
46. Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC,. Unique gene expression program of human germinal center T helper cells. Blood 2004; 104: 1952-60.
47. Manzo A, Vitolo B, Humby F, Caporali R, Jarrossay D, Dell'accio F, Ciardelli L, Uguccioni M, Montecucco C, Pitzalis C,. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum 2008; 58: 3377-87.
48. Takagi R, Higashi T, Hashimoto K, Nakano K, Mizuno Y, Okazaki Y, Matsushita S,. B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones. J Immunol 2008; 181: 186-9.
49. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ, Hackeng TM, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97-103.
50. Vanbervliet B, Bendriss-Vermare N, Massacrier C, Homey B, de Bouteiller O, Briere F, Trinchieri G, Caux C,. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 2003; 198: 823-30.
51. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, Muehlinghaus G, Szyska M, Radbruch A, Manz RA,. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003; 171: 1684-90.
52. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F,. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6: 741-50.